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Pulmonary arterial hypertension (PAH) is an aggressive vascular remodeling disease that
carries a high morbidity and mortality rate. Treprostinil (Remodulin) is a stable prostacyclin
analogue with potent vasodilatory and anti-proliferative activity, approved by the FDA and
WHO as a treatment for PAH. A limitation of this therapy is the severe subcutaneous site
pain and other forms of pain experienced by some patients, which can lead to significant
non-compliance. TWIK-related potassium channels (TREK-1 and TREK-2) are highly
expressed in sensory neurons, where they play a role in regulating sensory neuron
excitability. Downregulation, inhibition or mutation of these channels leads to enhanced
pain sensitivity. Using whole-cell patch-clamp electrophysiological recordings, we show,
for the first time, that treprostinil is a potent antagonist of human TREK-1 and TREK-2
channels but not of TASK-1 channels. An increase in TASK-1 channel current was
observed with prolonged incubation, consistent with its therapeutic role in PAH. To
investigate treprostinil-induced inhibition of TREK, site-directed mutagenesis of a
number of amino acids, identified as important for the action of other regulatory
compounds, was carried out. We found that a gain of function mutation of TREK-1
(Y284A) attenuated treprostinil inhibition, while a selective activator of TREK channels, BL-
1249, overcame the inhibitory effect of treprostinil. Our data suggests that subcutaneous
site pain experienced during treprostinil therapy may result from inhibition of TREK
channels near the injection site and that pre-activation of these channels prior to
treatment has the potential to alleviate this nociceptive activity.
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INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive vascular
remodeling disease which eventually leads to right ventricular
heart failure and premature death (Simonneau et al., 2019). A rare
disease, it has an estimated adult incidence of 5.8 per million, with
a higher incidence noted in females and a mean patient age
between 50–65 years (Galie et al., 2015; Leber et al., 2021). There
have been a number of advances in treatments, which have
transformed the quality of life of patients and reduced
mortality. However, despite these advances the prognosis for
sufferers remains poor with a 5-years survival rate of 61–65%
(Farber et al., 2015). It is widely surmised that PAH is initiated
following damage to the endothelium (Clapp and Gurung, 2015;
Madonna et al., 2015). Endothelial dysfunction leads to a decrease
in the production of the vasodilators prostacyclin (prostaglandin
I2; PGI2) and nitric oxide (NO) and an increase in the potent
vasoconstrictors, endothelin (ET-1) and thromboxane, which
combine to increase vascular tone, cell proliferation and
platelet aggregation in pulmonary arteries, to drive narrowing
of blood vessels (Morrell et al., 2009; Hemnes and Humbert,
2017). Given PGI2 is a key vasoactive regulator released by
endothelial cells in the pulmonary arteries, initial, therapeutic
management of PAH involved giving epoprostenol (synthetic
PGI2), but due to its short chemical and biological half-life led to
the development of PGI2 stable analogues, iloprost, beraprost and
treprostinil or more recently the non-prostanoid PGI2 receptor
agonist, selexipag. These therapies improve exercise capacity,
breathing, hemodynamic circulation, and patient survival in
various trials (Gomberg-Maitland and Olschewski, 2008;
Sitbon and Vonk Noordegraaf, 2017).
Treprostinil is a tricyclic benzindene analogue of PGI2 which
can be administered orally, subcutaneously (SC), intravenously or
inhaled (Lindegaard Pederson et al., 2020), with SC
administration (Remodulin) approved by the US Food and
Drug Administration and the World Health Organization. In a
number of studies, SC treprostinil has demonstrated significant
improvements in PAH symptoms and a reduction in adverse
events compared to other delivery mechanisms and other
synthetic PGI2 analogues (Picken et al., 2019). A potent
vasodilator, its therapeutic effects occur via activation of
specific prostanoid receptors (Clapp and Gurung, 2015;
Corboz et al., 2021). One major limitation of SC treprostinil
treatment is that severe site pain is the main significant adverse
event experienced by patients (Picken et al., 2019). The origin of
this site pain is unknown but is likely to involve the regulation of
ion channel activity in nociceptive sensory neurons.
The TWIK-related (TREK-1 and TREK-2) potassium
channels are members of the two-pore domain (K2P) family of
ion channels. TREK-1 and TREK-2 have been shown to be highly
expressed in sensory neurons, mainly in small nociceptors dorsal
root ganglion (DRG), with TREK-2 expression identified in IB4-
binding C-fibre nociceptors and TREK-1 expression in astrocytes
and neurons of the spinal cord, where they have been shown to
regulate spontaneous pain, neuropathic pain and hyperalgesia
(Alloui et al., 2006; Kang and Kim, 2006; Acosta et al., 2014;
Pereira et al., 2014; Viatchenko-Karpinski et al., 2018). Moreover,
TREK-1 and TREK-2 knockout (KO) mice show increased
sensitivity to a range of noxious stimuli, including heat,
mechanical and inflammatory agents (Alloui et al., 2006; Noel
et al., 2009; Pereira et al., 2014). Conversely, TREK channel
activation by riluzole, BL-1249, GI-530159, RNE28 and
C3001a was found, respectively, to eliminate oxaliplatin-
induced pain (Poupon et al., 2018), decrease tactile allodynia
in neuropathic rats (Garcia et al., 2020), reduce excitability of
small DRG neurons (Loucif et al., 2018), increase antinociceptive
activity in mouse models of pain (Busserolles et al., 2020) and
alleviate stimuli-induced hyperalgesia, allodynia and
inflammation in mice (Qiu et al., 2020).
The aim of this study was to determine whether treprostinil
had a direct inhibitory action on human cloned TREK-1 and
TREK-2 channels and thus provide a plausible explanation for the
severe site-pain experienced by PAH patients treated with this
drug. We investigated treprostinil effects on a number of TREK
channels with point mutations of amino acids required for the
modulatory action of a number of other known TREK channel
inhibitors and activators. Finally, using a selective activator of
TREK channels, we investigated whether we could overcome the
inhibitory effect of treprostinil on these channels. A preliminary
account of some of these data has been reported previously
(Cunningham et al., 2018).
MATERIALS AND METHODS
Most of the methods used here have been described previously
(Veale et al., 2014; Cunningham et al., 2019; Mathie et al., 2021a)
and will only be mentioned in brief below.
Mammalian Expression Plasmids
TREK-1 (KCNK2, Genbank™ NP_055032.1) and TASK-1
(KCNK3, NP_002237) cDNA were cloned into the
pcDNA3.1+ vector (Invitrogen, Carlsbad, CA, United States)
and TREK-2 (KCNK10, NP_612190.1) into PCMV6-XL-4
(OriGene Technologies, Inc. United States).
Mutagenesis
Ligand binding site and gating mutations were introduced by
site-directed mutagenesis into human TREK-1 (Q76A, I80A,
L102A, Y270A, Y284A, L289A) and TREK-2 (L320A,
K302Q) cDNA using the QuikChange kit (Agilent, CA,
United States) as previously described (Veale et al., 2014).
DNA sequencing was performed by DNA Sequencing and
Services (MRC/PPU, School of Life Sciences, University of
Dundee, Scotland).
Cell Culture
All experiments were performed using a modified human
embryonic kidney 293 cell line, tsA201 (European Collection
of Authenticated Cell Cultures; Sigma-Aldrich,
United Kingdom), prepared and maintained as previously
described (Veale et al., 2014). Cells were split when at a
confluency of 80%, resuspended in media to a concentration
of 7 × 104 and then 0.5 ml plated into a four-well plate containing
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13 mm poly-D-lysine coated (1 mg ml−1) glass coverslips, ready
for transfection the following day.
Transfection
Plasmids containing cDNA for either wildtype (WT) or mutated
TREK cDNA and a similar plasmid encoding the cDNA for green
fluorescent protein (GFP), were co-transfected at a concentration
of 0.5 µg using a modified calcium-phosphate protocol, as
previously described (Cunningham et al., 2019). All mutant
channels were expressed as homodimeric channels, where each
α-subunit expressed the incorporated mutation.
Whole-Cell Patch-Clamp Electrophysiology
Currents were recorded from GFP fluorescing tsA201 cells
expressing the cDNA of interest using whole-cell patch-clamp
in a voltage-clamp configuration and a step-ramp voltage
protocol using an extracellular solution composed of 145 mM
NaCl, 2.5 mM KCl, 3 mM MgCl2, 1 mM CaCl2 and 10 mM
HEPES (pH adjusted to 7.4 with NaOH) and an intracellular
pipette solution of 150 mM KCl, 3 mMMgCl2, 5 mM EGTA and
10 mM HEPES (pH adjusted to 7.4 with KOH). All experiments
were conducted at room temperature (20–25°C) and currents
were recorded using an Axopatch 1D patch clamp amplifier
(Molecular Devices, Sunnyvale, CA), filtered at 2 kHz and
digitized at 5 kHz. Control solution and modulatory
compounds were perfused at a rate of 4–5 ml min−1 for
∼3–6 min per experiment. For incubation studies, the cells
were incubated in either extracellular solution or extracellular
solution containing desired concentration of treprostinil for
20 min, prior to commencing electrophysiological recording
and for the duration of the experiment.
Data Analysis and Statistics
Data analysis of whole-cell outward current and analysis software
was as previously described in Cunningham et al. (2019). Whole-
cell outward currents were measured in picoamps (pA) and
recorded as the difference current between that measured at
−40 and −80 mV, normalized against cell capacitance (pF).
Current-voltage graphs were obtained from the voltage ramp
(−120 mV to +20 mV). All raw data traces were averages of all
cells recorded in each condition. Data were expressed as the mean
±95% Confidence Intervals (CI), and n represents the number of
individual cells, displayed as symbols on the graphs. Statistical
analysis used were either a one-way ANOVA with a post-hoc
Dunnett’s multiple comparisons test or a paired Student’s t-test.
Data was considered statistically different if p < 0.05 (*), p < 0.01
(**), p < 0.001 (***). Data from cells expressing mutant channels
were compared with matched control data from either WT
TREK-1 or WT TREK-2 recorded either simultaneously or
around the same calendar period and cell batch number.
Chemicals
BL-1249 was purchased from Sigma-Aldrich, United Kingdom
and dissolved in dimethyl sulfoxide (DMSO) to create a 10 mM
stock solution. Treprostinil (CAY10162) was purchased from
Cambridge Bioscience, United Kingdom (distributor for Cayman
Chemical Co.) and dissolved in DMSO to a concentration of
10 mM. Dilutions of the stock solutions were made directly into
the extracellular solution for use the same day.
RESULTS
TREK-1 and TREK-2 Channels are Potently
Inhibited by Treprostinil
We first investigated whether TREK-1 and TREK-2 channel
current was directly affected by PGI2 stable analogue,
treprostinil. Application of treprostinil over a concentration
range of 0.01–1 µM to cells expressing WT human TREK-1
channels resulted in a potent inhibition of whole-cell outward
current that gave a calculated 50% inhibitory concentration (IC50)
of 0.03 µM [95% confidence Intervals (CI): 0.01 to 0.06] estimated
from the difference between current measured at −40 mV and
−80 mV (Figure 1A). Using a maximal concentration of
treprostinil (1 µM), we observed a potent inhibition of whole-
cell outward current from 28.2 pA pF−1 [95% CI: 18.8 to 37.6, n 
8] in control to 5.3 pA pF−1 (95% CI: 1.4 to 9.2, n  8) when
treprostinil was present (Figures 1B,C). Similarly, application of
treprostinil over a concentration range of 0.01–1 µM to cells
expressing WT TREK-2 channels, resulted in a calculated IC50 of
0.04 µM (95% CI: 0.004 to 0.39) (Figure 1D). Where at a
concentration of 1 μM, the averaged TREK-2 current of
39.9 pA pF−1 (95% CI: 24.6 to 55.3, n  7) in control solution
was reduced to 18.7 pA pF−1 (95% CI: 7.3 to 24.0, n  7) in the
presence of treprostinil (Figures 1E,F).
Treprostinil Does Not Regulate TASK-1
Channels Directly
To understand whether this inhibitory effect of treprostinil on the
TREK channels was selective for this channel subtype, we tested it
on another member of the K2P family of channels, namely TASK-
1, which has been widely, implicated in PAH pathogenesis (Ma
et al., 2013; Boucherat et al., 2015; Antigny et al., 2016; Navas
et al., 2017; Cunningham et al., 2019). Unlike for TREK-1 and
TREK-2, treprostinil had neither an inhibitory nor activatory
effect on WT human TASK-1 channels, using the same
experimental protocol. Average current density for TASK-1
channels measured in control solution was 7.2 pA pF−1 (95%
CI: 1.4 to 13.0, n  5) compared to 6.5 pA pF−1 (95% CI: 3.2 to 9.8,
n  5) in the presence of treprostinil (1 μM; p > 0.05 (95% CI: −3.4
to 2.0), paired t-test, Figures 2A,B). As treprostinil appeared not
to inhibit the TASK-1 channel directly, we sought to investigate
whether treprostinil was able to exert an effect on TASK-1 via the
activation of signaling pathways, such as the protein kinases
(PKA)-dependent pathway, as has been previously suggested
(Olschewski et al., 2006; Corboz et al., 2021). To do this we
pre-incubated TASK-1 expressing tsA201 cells either in control
solution (untreated) or with the addition of 1 µM treprostinil
(treated) for 20 min and then measured currents in each
condition. An increase (p < 0.05, unpaired t-test) in current
density was observed in treprostinil-incubated cells (9.4 pA pF−1
[95% CI: 7.7 to 11.1, n  15]), compared with untreated control-
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incubated cells (6.0 pA pF−1 [95% CI: 4.8 to 7.2, n  17], Figures
2C,D), with an average current increase of 36.2%.
Treprostinil Inhibition of TREK-1 is Not
Affected by Known Allosteric
Ligand-Binding Site Mutations Located in
the Extracellular Cap
We next sought to elucidate the molecular mode of action of
treprostinil on the TREK channel. It has previously been shown
that some inhibitors of TREK channels act by binding to sites in
the extracellular cap of these channels resulting in a block of the
ion conduction pathway (Luo et al., 2017). We mutated three
residues, glutamine (Q) 76, isoleucine (I) 80 and leucine (L) 102
to alanine’s (A) and compared the treprostinil-induced inhibition
of these mutant channels to WT TREK-1 since mutations
of these sites has been shown to reduce the effectiveness of
N-(4-cholorphenyl)-N-(2-(3,4-dihydrosioquinolin-2 (1H)-yl)-2-
oxoethyl) methanesulfonamide (TKDC)-induced allosteric
conformational transitions of the extracellular cap (Luo et al.,
2017). Alanine substitution of these amino acids (Q76A, I80A
and L102A) into TREK-1 resulted in functional homodimeric
channels where the mutation is expressed on both α-subunits,
with whole-cell current densities (pA pF−1) either similar to WT
(Q76A and L102A) or slightly increased (I80A, p < 0.03, one-way
ANOVA, followed by Dunnett’s multiple comparisons test,
Figures 3A,E,I, M). The average whole-cell current was
28.3 pA pF−1 (95% CI: 21.0 to 35.7, n  10) for WT;
35.6 pA pF−1 (95% CI: 25.8 to 45.4, n  7) for Q76A;
50.4 pA pF−1 (95% CI: 28.2 to 72.6, n  8) for I80A;
31.1 pA pF−1 (95% CI: 23.7 to 38.6, n  11) for L102A. Ramp
changes in holding potential from −120 to +20 mV showed that
mutant channels were outwardly rectifying with mean zero
current reversal potentials that were not significantly different
(p > 0.05, one-way ANOVA followed by a Dunnett’s
multiple comparisons test) from WT channels (−81.4 mV
[95% CI:  −87.3 to -75.6, n  7] for Q76A; −86.1 mV [−89.9
to −82.3, n  8] for I80A; −85.6 mV [−89.7 to −81.5, n  11] and
−83.1 mV [95% CI:  −87.3 to −78.9, n  10] forWT) and close to
the expected reversal potential for a potassium selective channel
under these experimental conditions.
We then investigated the influence of these mutations on the
inhibitory effect produced by treprostinil on WT TREK-1
channels. Application of treprostinil (1 µM), was found to
potently inhibit the current of all three mutated channels
(Q76A: 4.0 pA pF−1 [95% CI: 3.0 to 5.0, n  5]; I80A:
12.7 pA pF−1 [95% CI: 4.5 to 21.0, n  6]; L102A: 3.2 pA pF−1
[95% CI: 2.1 to 4.3, n  8]), similar to WT channels (5.3 pA pF−1
[95% CI: 1.4 to 9.2, n  10] (Figures 3B,F,J,N). Overall inhibition
of the current by treprostinil for each mutant channel was 89%
(95% CI: 86.3 to 91.6, n  5) for Q76A, 78.2% (95% CI: 68.5 to
87.8, n  6) for I80A and 88% (95% CI: 85.3 to 90.3, n  5) for
FIGURE 1 | Effect of treprostinil on human cloned TREK-1 and TREK-2 channels (A) Concentration-response curve for treprostinil inhibition of human TREK-1
current. Error bars represent standard error of the mean (SEM) (B) Measurement of whole-cell TREK-1 current (pA) normalized against cell capacitance (pF) in control
2.5 mM [K+] solution (black symbols) and following acute application of treprostinil (1 μM, blue symbols, ***p < 0.0002 (95%CI: −31.4 to −14.5), paired t-test (C)Current-
voltage plot of TREK-1 currents (average of n  8 cells) under control conditions (black line) and in the presence of treprostinil (1 μM, average of n  8 cells, blue line)
recorded over a voltage ramp (−120 mV to +20 mV) (D)Concentration-response curve for treprostinil inhibition of human TREK-2 current (E)Measurement of whole-cell
TREK-2 current (pA pF−1) in control and following acute application of treprostinil (1 μM, **p < 0.001 [95% CI: −34.43 to −14.18]), paired t-test (F)Current-voltage plot of
TREK-2 in control (black line, n  7) and in the presence of treprostinil (1 μM, n  7, blue line).
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L102A which were similar (p > 0.05) toWT, 82% (95% CI: 70.4 to
93.6, n  8), (Figures 3C,G,K,O), represented by exemplar time
courses for each condition (Figures 3D,H,L,P).
Disruption of Known Contact Binding Sites
for the Antagonist Norfluoxetine and
Activators BL-1249,ML335 andML402Does
Not Interfere With Treprostinil Inhibition of
Either TREK-2 or TREK-1
The antidepressant, norfluoxetine an active metabolite of fluoxetine
(Prozac) and a known inhibitory molecule of the TREK family
(Kennard et al., 2005; Heurteaux et al., 2006) has been resolved
bound within the intramembrane fenestrations, located below the
selectivity filter of TREK-2 (Dong et al., 2015). A number of amino
acids were identified as contact points for norfluoxetine, including a
phenylalanine (F) at position 316 (F316) and a leucine at position 320
(L320) in the TM4 region of the channel. Furthermore, mutation of
L320 was found to reduce norfluoxetine’s inhibition of TREK-2
(Dong et al., 2015). The same amino acid on the TM4 of TREK-1 has
also been identified as a contact point for the activator, BL-1249 and
mutation of this corresponding site, reduced the effectiveness of the
compound (Schewe et al., 2019). As the inhibitory profile of
treprostinil on TREK-2 and TREK-1 is similar to that observed
for fluoxetine and norfluoxetine (Kennard et al., 2005; Dong et al.,
2015) we looked to determine whether treprostinil was exerting its
inhibitory effect via the equivalent amino acids on the
intramembrane fenestrations of both TREK-2 and TREK-1.
To assess this, we mutated L320 on TREK-2 and the
corresponding amino acid on the TM4 of TREK-1, L289, to an
alanine. Interestingly, treprostinil-mediated inhibition of both TREK-
2/L320A and TREK-1/L289Amutated channels was unchanged. The
expressed TREK-2/L320A mutated homodimeric channels gave
functional whole cell currents of 27.2 pA pF−1 (95% CI: 21.4 to
33.0, n  13) that were smaller (p < 0.05, unpaired t-test) in size
than WT channels 39.9 pA pF−1 (95% CI: 24.6 to 55.3, n  7) under
similar experimental conditions. Application of 1 µM treprostinil
significantly reduced (p < 0.05, paired t-test) TREK-2/L320A channel
currents from 23.5 pA pF−1 (95% CI: 12.1 to 34.9, n  6) to
6.0 pA pF−1 (95% CI: 2.4 to 9.7, n  6) (Figure 4A). Overall, the
average inhibition of the TREK-2/L320A current by 1 µM treprostinil
was 74% (95%CI: 68.4 to 80.0,n 6), compared to 61% (95%CI: 46.1
to 75.9, n  7) for WT TREK-2 channels (Figure 4B).
Similarly, the expressed TREK-1/L289A mutated homodimeric
channels gave average whole cell currents of 20.3 pA pF−1 (95% CI:
11.6 to 29.05, n 7) that were similar (p> 0.05, unpaired t-test) in size
FIGURE 2 | Effect of treprostinil on human TASK-1 (A) Measurement of whole-cell TASK-1 current (pA pF−1) in control solution (black symbols) and following
application of treprostinil (1 μM, blue symbols, p  0.506 [95% CI: −53.06 to 12.66]); paired t-test (B) Exemplar time course, demonstrating the effect of 1 µM treprostinil
(drug application is represented by the blue line), on whole-cell TASK-1 current (pA) over time (s). Each point is a 50 s average of the difference current (C) Bar graphs of
current densities (pA pF−1) from cells transiently expressing WT TASK-1 measured in control extracellular solution and when cells have been incubated in 1 µM
treprostinil (>20 min), **p  0.0013 [95%CI: 1.4 to 5.3]), unpaired t-test. Error bars represent the 95% CI (D) Current-voltage plot of TASK-1 in control conditions (black
line) and treprostinil (1 μM, blue line) recorded over a voltage ramp (−120 mV to +20 mV).
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toWTTREK-1 channels andwhichwere significantly reduced in size
(p < 0.05, paired t-test) by application of 1 µM treprostinil to
5.7 pA pF−1 (95% CI: 0.82 to 10.64, n  7) (Figure 4C). Overall,
the average inhibition of the TREK-1/L289A current by 1 µM
treprostinil was 72% (95% CI: 57.8 to 86.2, n  7), similar to that
inhibition observed for WT TREK-1 channels 82% (95% CI: 70.4 to
93.6, n  8, p > 0.05, unpaired t-test) (Figure 4D).
Likewise, disruption of the cryptic modulator pocket identified
in TREK, which has been shown to bind the activators ML335
and ML402, regulating the C-type gate (Lolicato et al., 2017) did
not reduce the effectiveness of treprostinil on TREK-2. Mutation
of the lysine (K) 302 in the TM4 of TREK-2 which sits adjacent
to the selectivity filter of the channel, to a glutamine (K302Q),
gave whole-cell currents of 35.7 pA pF−1 (95% CI: 22.2 to
49.1, n  6) that were significantly reduced (p < 0.05) to
17.19 pA pF−1 (95% CI: 7.6 to 26.8, n  6) in the presence of
1 µM treprostinil (Figure 4E). Overall average channel
inhibition was 53.5% (95% CI: 36.6 to 70.4, n  6), which
was not significantly different (p > 0.05, unpaired t-test) from
WT TREK-2 inhibition (Figure 4F).
A recent paper by Qiu et al. (2020), identified Y270 on TREK-1
(Y285 in their human TREK-1 construct, NM_001017425.3), as
an important amino acid regulating the effectiveness of the anti-
nociceptive activator, C3001a. In our hands, TREK-1 channels
with the mutated amino acid Y270A carried negligible current,
3.3 pA pF−1 (95% CI: 2.1 to 4.5, n  6) in the absence of any
activator (Supplementary Figure S1), so it was not possible to
determine the effect of this mutation on inhibition by treprostinil.
A Gain-of-Function Mutation, Y284A in
TREK-1, Attenuates the Inhibitory Effect of
Treprostinil
To try and elucidate further how treprostinil might be conferring
its inhibitory effects on the TREK channels, we considered a
known gain-of-function (GOF) mutation that affects the gating of
FIGURE 3 | Effect of treprostinil on extracellular allosteric ligand-binding site mutations in TREK-1. Graphs of current densities (pA pF−1) from cells transiently
expressing WT TREK-1 (A, B), TREK-1/Q76A (E, F), TREK-1/I80A (I, J) and TREK-1/L102A (M, N) in control extracellular solution and in the presence of 1 µM
treprostinil. Error bars represent the 95% CI and symbols represent currents measured from individual cells (C, G, K, O) Box and Whisker plots of treprostinil (1 µM)
inhibition of WT TREK-1, TREK-1/Q76A, TREK-1/I80A and TREK-1/L102A. Bars represent the min and max inhibition and lines the median inhibition, while
symbols represent the individual, data points (D, H, L, P) Exemplar time courses, demonstrating the effect of 1 µM treprostinil (application shown by the blue line), on
whole cell current (pA), for each channel type.
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the channel (Y284A). This amino acid has previously been shown
to attenuate the effect of the activator, flufenamic acid (FFA) and
the effect of arachidonic acid (Veale et al., 2014; Ma and Lewis,
2020) and antagonize the inhibitory effects of norfluoxetine and
spadin (McClenaghan et al., 2016; Ma and Lewis, 2020). As
previously reported (Veale et al., 2014) mutation of Y284 to
an alanine in TREK-1, resulted in channels with large outward
currents of 95.8 pA pF−1 (95% CI: 74.6 to 117.0, n  5) which were
significantly larger (p < 0.05, unpaired t-test) than WT TREK-1,
24.2 pA pF−1 (95% CI: 18.3 to 30.1, n  8) and in agreement with
channels having a higher Po (Proks et al., 2020). Application of
1 µM treprostinil was found to still significantly reduce (p < 0.05,
FIGURE 4 | Effect of treprostinil on mutated TREK-2/L320A, TREK-1/L289A and TREK-2/K302Q (A) Measurement of whole-cell TREK-2/L320A current (pA pF−1)
in control (n  6) and following application of treprostinil (1 μM, n  6, **p  0.003; paired t-test) (B)Comparison of the inhibition ofWT TREK-2 and TREK-2/L320A current
by treprostinil (1 µM) calculated as the difference of current measured in control, with that measured after exposure to treprostinil, expressed as a percentage, displayed
as a Box and Whiskers plot. Bars represent the min and max inhibition and lines the median inhibition, for each channel type. Points represent the individual data
points (C)Measurement of whole-cell TREK-1/L289A current (pA pF−1) in control (n  7) and following application of treprostinil (1 μM, n  7, **p  0.002; paired t-test) (D)
Comparison of the inhibition of WT TREK-1 and TREK-1/L289A current by treprostinil (1 µM), expressed as a percentage, displayed as a Box and Whiskers plot (E)
Measurement of whole-cell TREK-2/K302Q current (pA pF−1) in control (n  6) and following application of treprostinil (1 μM, n  7, **p < 0.001; paired t-test) (F)
Comparison of the inhibition of WT TREK-2 and TREK-2/K302Q current by treprostinil (1 µM), expressed as a percentage, displayed as a Box and Whiskers plot.
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paired t-test) TREK-1/Y284A channel currents to 40.0 pA pF−1
(95% CI: 22.5 to 57.5, n  5) (Figures 5A,B,D). Although, current
through the TREK-1/Y284A mutant channel was still
substantially inhibited (58%) by treprostinil, the degree of
inhibition was significantly reduced (p < 0.05, unpaired t-test)
fromWT TREK-1 inhibition (Figures 5C,D), suggesting that the
effect of the compound is influenced by gating at the channel
selectivity filter (McClenaghan et al., 2016; Proks et al., 2020).
BL-1249, an Activator of TREK Current,
Antagonizes Treprostinil Inhibition of
TREK-1 and TREK-2 Current
The negatively charged activator, BL-1249 is an established
activator of TREK-1 and TREK-2 channels (Tertyshnikova
et al., 2005; Veale et al., 2014; Pope et al., 2018; Schewe et al.,
2019; Mathie et al., 2021b). BL-1249 (1 µM) significantly
enhanced (p < 0.05) TREK-1 and TREK-2 control current by
144% (95% CI: 72.8 to 214.5, n  8) and 192% (95% CI: 135.2 to
248, n  5) (see also Table 1, C2, D2; Figures 6A,B, blue line).
Once, BL-1249-activated TREK currents were stable (2–4 min)
the solution was switched to one containing both BL-1249 (1 µM)
and treprostinil (1 µM) (Figures 6A,B gray line). The amount of
BL-1249-activated current remaining after treprostinil inhibition,
was measured oncemaximum inhibition by 1 µM treprostinil was
observed (Table 1, C3, D3). Interestingly, for both TREK-1 and
TREK-2, the current in the combined presence of treprostinil and
BL-1249 (C3, D3) was not significantly different (p > 0.05) from
the original starting current (C1, D1).
DISCUSSION
Subcutaneous infusion of treprostinil in patients with PAH,
confers significant improvements in their exercise capacity and
hemodynamics, however these benefits are compromised by pain
experienced at the subcutaneous infusion site (Simonneau et al.,
2002; McLaughlin et al., 2003; Picken et al., 2019). Treprostinil
treatment has also been shown to have several other painful side
effects, including jaw pain, headache, and pain in extremities
(Picken et al., 2019). In this study we have shown that treprostinil
potently and reversibly inhibits, both human TREK-1 and TREK-
2 channels. TREK-1 and TREK-2 channels are strongly
implicated in pain signaling pathways and both are expressed
abundantly within sensory neurons (Alloui et al., 2006; Marsh
et al., 2012).
In contrast, TASK-1 channels were not inhibited by
treprostinil. TASK-1 channels are highly expressed in human
PASMCs and have a role in regulating the resting membrane
potential of these cells (Olschewski et al., 2006). Downregulation,
FIGURE 5 | Effect of treprostinil on mutated TREK-1/Y284A (A)Measurement of whole-cell TREK-1/Y284A current (pA pF−1) in control (n  5) and following acute
application of treprostinil (1 μM, n  5, ***p  0.0004; paired t-test) (B)Current-voltage relationship of TREK-1/Y284A currents (average of n  5 cells) in control conditions
(black line) and treprostinil (1 μM, average of n  5 cells, blue line) recorded over a voltage ramp (−120 mV to +20 mV) (C)Comparison of the inhibition of WT TREK-1 and
TREK-1/Y284A current by treprostinil (1 µM) calculated as the difference of current measured in control, with that measured after exposure to treprostinil,
expressed as a percentage, displayed as a Box andWhiskers plot (**p < 0.009, unpaired t-test) (D) Exemplar time course plot for TREK-1/Y284A current demonstrating
the effect of changing from an extracellular control solution to one containing treprostinil (1 μM, blue line).
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inhibition or inactivating mutations of TASK-1 channels have
been shown to contribute to detrimental vascular remodeling in
the PAH disease phenotype (Ma et al., 2013; Boucherat et al.,
2015; Antigny et al., 2016; Navas et al., 2017; Cunningham et al.,
2019), while pharmacological interventions that enhances TASK-
1 channel current have been found to be beneficial in PAH
treatment (Olschewski et al., 2006; Ma et al., 2013; Antigny et al.,
2016; Cunningham et al., 2019). Treprostinil has previously been
demonstrated to enhance TASK-1 channel current indirectly via
a protein kinase A-dependent pathway (Olschewski et al., 2006).
This is in agreement with the data obtained here, where
prolonged incubation in treprostinil was found to induce an
enhancement of current through TASK-1 channels.
Regulation of TREK Channels by
Treprostinil
A distinguishing feature of K2P channels is the existence of an
extracellular cap domain, which causes the formation of two
tunnel-like side portals permitting bilateral extracellular ion
conduction from the selectivity filter (Brohawn et al., 2013;
Dong et al., 2015). This structural feature underlies the
insensitivity of K2P channels to classical K channel pore
blockers such as TEA (Brohawn et al., 2012; Miller and
Long, 2012). Some small molecules, such as ruthenium red
and zinc exert their inhibitory effect through sites on the
extracellular cap of TASK channels (Czirják and Enyedi, 2003;
Musset et al., 2006; Clarke et al., 2008). More recently, the
extracellular cap in TREK channels has been demonstrated to
be important in transducing the effect of small ligands, such as
TKDC and ruthenium red, via allosteric conformational
changes of the bilateral side portals that subsequently
interrupts ion conduction (Braun et al., 2015; Luo et al.,
2017). In order to elucidate the molecular mechanism by
which treprostinil inhibits TREK channels, we studied its
effect on three identified mutations in the extracellular cap,
which have been shown to be important for TKDC binding to
TREK-1 channels (Luo et al., 2017). Surprisingly, none of
these mutations altered the inhibitory effect of treprostinil on
TREK-1 channels, suggesting that treprostinil does not exert
its effect by binding to this region of the extracellular cap and
blocking the ion conduction pathway of the channel.
TABLE 1 | Effect of treprostinil inhibition on BL-1249 preactivated TREK-1 and TREK-2 channels. Measurement of whole-cell TREK-1 current (pA pF−1) in control (A1) and
then following application of 1 µM treprostinil (A3) (***p < 0.0004 [95% CI: −31.4 to −14.5], paired t-test). Measurement of TREK-2 current in control (B1) and then
following application of 1 µM treprostinil (B3) (**p < 0.001 [95% CI: −34.4 to −14.1], paired t-test). Measurement of whole-cell TREK-1 current in control (C1) and following
application of 1 µM BL-1249 (C2) (**p < 0.002 [95% CI: −69.6 to −17.10], one-way ANOVA, followed by Dunnett’s multiple comparisons test) and then following application
of 1 µM treprostinil to the BL-1249-activated current (C3) (p > 0.05 [−31.9 to 11.76] one-way ANOVA, followed by Dunnett’s multiple comparisons test). TREK-2 current
in control (D1) and following application of 1 µM BL-1249 (D2) (**p < 0.003 [95% CI: −69.6 to −17.1], one-way ANOVA, followed by Dunnett’s multiple comparisons test)





— Current density in
treprostinil (1 µM)
A TREK-1 28.2 pA pF−1 (95% CI: 18.8–37.6) n  8 ― ***5.3 pA pF−1 (95% CI: 1.4–9.2) n  8
B TREK-2 39.9 pA pF−1 (95% CI: 24.6–55.3) n  7 ― **15.7 pA pF−1 (95% CI: 7.3–24.0) n  7
Current density in control Current density in BL-1249 (1 µM) Current density in BL-1249 (1 µM) + treprostinil (1 µM)
C TREK-1 25.3 pA pF−1 (95% CI: 18.6–31.9) n  8 **56.9 pA pF−1 (95% CI: 45.4–68.3) n  8 35.3 pA pF−1 (95% CI: 14.1–56.6) n  8
D TREK-2 22.9 pA pF−1 (95% CI: 14.5–31.3) n  5 **66.2 pA pF−1 (95% CI: 39.6–92.7) n  5 35.4 pA pF−1 (95% CI: 16.8–53.9) n  5
FIGURE 6 | Treprostinil inhibition of TREK-1 and TREK-2 channels pre-activated by BL-1249 (A) Exemplar time course plot demonstrating the effect of 1 µM BL-
1249 (application shown by the blue line), followed by the combined application of 1 µM BL-1249 and 1 µM treprostinil (gray line) then returning to 1 µM BL-1249 alone,
on TREK-1 whole cell current (B) Exemplar time course plot demonstrating the effect of 1 µMBL-1249 (blue line), followed by the combined application of 1 µM BL-1249
and 1 µM treprostinil (gray line) on TREK-2 whole cell current.
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Another TREK channel antagonist and antidepressant agent,
norfluoxetine (Kennard et al., 2005), exerts it effects through
binding to a highly conserved fenestration adjacent to the pore
filter entrance of TREK-2 (Dong et al., 2015). Contact points for
norfluoxetine on TREK-2 were identified in the TM4 region of
the channel and mutation of L320 was found to reduce
norfluoxetine inhibition of TREK-2 (Dong et al., 2015). The
equivalent amino acid on the TM4 of TREK-1, L289 has also
been identified as a contact point for the TREK-1 agonist, BL-
1249, mutation of which reduced the effectiveness of the
compound (Schewe et al., 2019). We determined whether
treprostinil was exerting its inhibitory effect via the equivalent
amino acids on the intramembrane fenestrations of both TREK-1
and TREK-2, however, mutations of antagonist sites in the TM4
region of both TREK-1 and TREK-2, did not alter treprostinil
inhibition of the channels. This would imply that treprostinil does
not bind to the same site on TREK channels as norfluoxetine.
Lolicato et al. (2017) showed that two small molecule
activators of TREK channels, ML335 and ML402, were able
to influence the C-type gate independently of the TM4 region
of the channel, by binding directly to the C-type gate, coined
the “cryptic selectivity-filter binding site” (Lolicato et al.,
2017). A lysine in TREK-1 (K271) was identified as being
an important interaction site for these compounds and
essential for activation (Lolicato et al., 2017). Mutation of
the equivalent lysine in TREK-2 (K302Q) did not alter the
effect of treprostinil.
A tyrosine in the TM4 region (Y270 in the TREK-1 isoform
used here) was recently shown to be important in regulating the
effectiveness of an anti-nociceptor activator, C3001a (Qiu et al.,
2020). We found, however, that this mutation carried negligible
current at −40 mV in the absence of a high concentration of a
TREK-1 channel activator and thus were unable to test whether it
interfered with treprostinil inhibition.
Attenuation of Treprostinil Inhibition of
TREK Channels
The C-type selectivity filter gate is highly sensitive to intracellular
modulators such as heat, mechanical stress and intracellular
acidosis (Patel et al., 1998.; Maingret et al., 1999; Bagriantsev
et al., 2011; Piechotta et al., 2011; Mathie et al., 2021b) and
extracellular regulators such as protonation (Cohen et al., 2008;
Sandoz et al., 2009). A number of amino acids in the pore lining
TM4 helix of TREK-1 close to the selectivity filter have been
identified as important for the regulation of channel gating.
Mutation of these amino acids give rise to a GOF that in turn
interferes with channel gating and regulation by both external
and internal regulators (Bagriantsev et al., 2011; Bagriantsev et al.,
2012; Veale et al., 2014). We have previously shown that a
tyrosine at position 284 in TREK-1 causes a GOF that
substantially reduces activation by the fenamate, flufenamic
acid and by BL-1249, reducing ligand efficacy (Veale et al.,
2014). This tyrosine residue, located within the “hinge” of the
TM4 domain of TREK channels, a critical area involved in the
movement of these channels between different “up” and “down”
states (Dong et al., 2015), has been shown to alter the channels
sensitivity to stretch, norfluoxetine and BL-1249 (McClenaghan
et al., 2016; Aryal et al., 2017; Schewe et al., 2019). Mutation of
this amino acid in TREK-2 (Y315A, Dong et al., 2015) pushes the
channel into an activated state, with increased macroscopic
currents and higher resting open probability (Po)
(McClenaghan et al., 2016; Proks et al., 2020). This region has
also been shown to be important in the binding of both channel
activators and inhibitors in other K channels (Hosaka et al., 2007;
Perry et al., 2010; Garg et al., 2011). Interestingly, we found that
the equivalent, Y284A, GOF mutation of TREK-1, significantly
attenuated the effect of treprostinil on these channels, suggesting
that treprostinil was much less efficient at inhibiting these
channels when it was gated open (McClenaghan et al., 2016;
Proks et al., 2020). Thus, although treprostinil does not bind to
the same site as norfluoxetine, block by treprostinil is also gating-
state dependent and is more effective when TREK channels are in
their lower open probability state, characterized by the TM4
regions of the channels being in their “down” conformation
(Dong et al., 2015; McClenaghan et al., 2016). As such, the
effect of treprostinil is influenced by “C-type” selectivity filter
gating of the channel (Chemin et al., 2005; Bagriantsev et al.,
2011, Bagriantsev et al., 2012; Dong et al., 2015; McClenaghan
et al., 2016). It is of interest that inhibition by treprostinil of
TREK-1 (∼75%) and TREK-2 (∼55%) is incomplete which is
consistent with the presence of multiple gating states of TREK
channels (McClenaghan et al., 2016), one or more of which is
resistant to block by the compound.
Since gating of the channel influenced treprostinil inhibition,
we determined whether gating the channel “open” using a
pharmacological activator, BL-1249 (Tertyshnikova et al., 2005;
Veale et al., 2014) would also attenuate the inhibitory effect of
treprostinil. We found that pre-application of BL-1249 to both
TREK-1 and TREK-2 channels did indeed attenuate the
inhibition by treprostinil, as we saw with the GOF mutation.
Indeed, the treprostinil inhibited current was greater than the
original baseline starting current, pre-BL-1249 treatment. BL-
1249 pre-activation of TREK-1 current has been shown to
antagonize the effect of the inhibitor, spadin (Ma and Lewis,
2020), a similar effect to that observed for TREK-2 current with
the activator ML335 and inhibitor norfluoxetine (Lolicato et al.,
2017; Proks et al., 2020).
Given that TREK channels are known to participate in acute
nociception it is possible that the inhibition of TREK channels by
treprostinil is responsible for the subcutaneous site pain
experienced by PAH patients. This is similar to the acute pain
induced by oxaliplatin when used in cancer therapy (Poupon
et al., 2018) which is attributable to a down regulation of TREK
and TRAAK channels (Pereira et al., 2021). The mean plasma
concentration of treprostinil in patients is around 10–20 ng/ml
(25–50 nM) which is in the range of the IC50s seen here for block
of TREK-1 and TREK-2 channels. At the site of subcutaneous
injection however, this concentration would be higher and able to
cause substantive block of TREK channels. The potent
antinociceptive benefits of pharmacologically upregulating
TREK-1 and TREK-2 channels has recently been shown in
vivo with a series of substituted acrylic acid analogues and
C3100a (Vivier et al., 2017; Qiu et al., 2020). Similarly,
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activation of TREK channels by riluzole can overcome the
neuropathic pain induced by oxaliplatin (Poupon et al., 2018).
It is proposed that the use of a specific activator of TREK
channels, applied topically, could potentially provide a safe
therapeutic strategy to overcome the excruciating pain that is
experienced by patients receiving treprostinil injection.
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